by Eric Christianson | Feb 8, 2023 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Attention Deficit Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder in children, occurring almost twice as often in boys compared to girls. The most observed symptoms are inattention, hyperactivity, and impulsivity, but the primary...
by Eric Christianson | Jan 29, 2023 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Tardive dyskinesia (TD) is a movement disorder that can cause repetitive, uncontrolled muscle movements in the face, neck, arms, and legs. In this article, we provide an update on tardive dyskinesia therapies. Symptoms of TD can include a mixture of orofacial...
by Eric Christianson | Dec 4, 2022 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Trazodone is a medication I see used in my geriatric practice on a daily basis. It is classified as a “serotonin modulator”. It has some serotonin antagonist action at lower doses and may have more serotonin agonist effects at higher dosages. In this...
by Eric Christianson | Nov 23, 2022 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Lorazepam and clonazepam are both from the benzodiazepine family. I see them both used in clinical practice on a regular basis. While their pharmacology actions are essentially identical, there are some pharmacokinetic, dosage form, and indication differences you...
by Eric Christianson | Oct 23, 2022 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Z-drugs, otherwise known as benzodiazepine receptor agonists, are used to help patients with insomnia that is associated with difficulty falling asleep (sleep latency), difficulty staying asleep (sleep maintenance), or not feeling rested after a night’s sleep (sleep...
by Eric Christianson | Oct 16, 2022 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Benzodiazepines are prescribed to over 5% of the United States population and that number continues to grow. This class of medications is responsible for facilitating the binding of the inhibitory neurotransmitter GABA-A at various GABA receptors throughout the...
